title: Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.
abstract: BACKGROUND
  The preventive effects of histamine 2 receptor antagonists vs. proton pump inhibitors on low-dose aspirin (LDA)-related gastroduodenal mucosal injury have not been fully investigated. We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months.
  
  
  METHODS
  Of 84 eligible patients, two taking 40 mg/day of famotidine and four taking 15 mg/day of lansoprazole refused to undergo upper gastrointestinal endoscopy. Ultimately, we performed upper gastrointestinal endoscopy in 78 patients taking either 40 mg/day of famotidine (group F, n = 31) or 15 mg/day of lansoprazole (group L, n = 47). The prevalence of gastroduodenal ulcers or erosions and the magnitude of gastric mucosal injury evaluated using modified Lanza scores were compared between the two groups.
  
  
  RESULTS
  No patients in either group had gastroduodenal ulcers. Gastroduodenal erosions were more prevalent in group F than in group L (48.4% vs. 17.0%, p = 0.005). The modified Lanza scores (mean ± SD) were significantly higher in group F than in group L (0.9 ± 1.3 vs. 0.3 ± 0.7, p = 0.007). A multivariate logistic regression analysis showed that the use of lansoprazole was negatively associated with gastroduodenal erosions.
  
  
  CONCLUSIONS
  This study suggests that 15 mg/day of lansoprazole may be more effective in preventing the development of LDA-related gastroduodenal erosions than 40 mg/day of famotidine. The preventive effects of these two regimens on the development of LDA-related gastroduodenal ulcers require further investigation.
authors.affiliation: Internal Medicine 2, Oita University, Yufu, Japan. akira@oita-u.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Tamura
authors.forename: Kazunari
authors.initials: K
authors.lastname: Murakami
authors.forename: Junichi
authors.initials: J
authors.lastname: Kadota
mesh_terms: D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D004724:Endoscopy; D015738:Famotidine / Q000008:administration & dosage*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000453:epidemiology* / Q000517:prevention & control; D015995:Prevalence; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000897:Anti-Ulcer Agents; D013256:Steroids; D064747:Lansoprazole; D015738:Famotidine; D001241:Aspirin